ATE261972T1 - 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde - Google Patents

2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde

Info

Publication number
ATE261972T1
ATE261972T1 AT99973293T AT99973293T ATE261972T1 AT E261972 T1 ATE261972 T1 AT E261972T1 AT 99973293 T AT99973293 T AT 99973293T AT 99973293 T AT99973293 T AT 99973293T AT E261972 T1 ATE261972 T1 AT E261972T1
Authority
AT
Austria
Prior art keywords
heptan
diazabicyclo
medicine
derivatives
production
Prior art date
Application number
AT99973293T
Other languages
English (en)
Inventor
Alistair Lochead
Samir Jegham
Alain Nedelec
Jean Jeunesse
Frederic Galli
Luc Even
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE261972T1 publication Critical patent/ATE261972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99973293T 1998-12-04 1999-12-01 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde ATE261972T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9815325A FR2786769B1 (fr) 1998-12-04 1998-12-04 Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
PCT/FR1999/002974 WO2000034284A1 (fr) 1998-12-04 1999-12-01 Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE261972T1 true ATE261972T1 (de) 2004-04-15

Family

ID=9533581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99973293T ATE261972T1 (de) 1998-12-04 1999-12-01 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde

Country Status (9)

Country Link
US (1) US6635645B1 (de)
EP (1) EP1144413B1 (de)
JP (1) JP2002531568A (de)
AR (1) AR021533A1 (de)
AT (1) ATE261972T1 (de)
AU (1) AU1392900A (de)
DE (1) DE69915693D1 (de)
FR (1) FR2786769B1 (de)
WO (1) WO2000034284A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361525C (en) * 1999-01-29 2009-12-08 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
DE60008866T2 (de) 1999-05-04 2005-01-27 Neurosearch A/S Heteroaryl diazabicycloalkene, deren herstellung und verwendung
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
CA2409644A1 (en) 2000-05-25 2001-11-29 Targacept, Inc. Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
US6552015B2 (en) * 2000-08-03 2003-04-22 Pfizer Inc. Azabicycloalkane derivatives and therapeutic uses thereof
US7329754B2 (en) 2001-03-02 2008-02-12 Neurosearch A/S 2,5-diazabicyclo[2.2.1]heptane derivatives
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
MXPA04010966A (es) * 2002-05-07 2005-01-25 Neurosearch As Derivados novedosos de biarilo diazabiciclico.
CN102657651A (zh) * 2002-12-06 2012-09-12 范因斯坦医学研究院 用α 7受体结合胆碱能激动剂抑制炎症
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
GB0311201D0 (en) * 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
JP5144930B2 (ja) 2003-08-18 2013-02-13 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジン
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
JP2007520526A (ja) * 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ コリン作動性受容体モジュレーターとしてのジアザビシクロアリール誘導体
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
WO2006087305A1 (en) 2005-02-16 2006-08-24 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
ATE495178T1 (de) 2005-02-16 2011-01-15 Neurosearch As Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin- acetylcholin-rezeptoren
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
FR2889847B1 (fr) * 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
EP2322168A1 (de) 2007-04-02 2011-05-18 Parkinson's Institute Verfahren und Zusammensetzung zur Verringerung der Nebenwirkungen von therapeutischen Behandlungen
WO2009135495A1 (en) * 2008-05-07 2009-11-12 H. Lundbeck A/S Method for treating cognitive deficits
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
EP3565617A1 (de) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Vorrichtungen und verfahren zur transdermalen wirkstofffreisetzung
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US4994460A (en) * 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives

Also Published As

Publication number Publication date
FR2786769A1 (fr) 2000-06-09
EP1144413A1 (de) 2001-10-17
AU1392900A (en) 2000-06-26
FR2786769B1 (fr) 2002-10-25
US6635645B1 (en) 2003-10-21
DE69915693D1 (de) 2004-04-22
EP1144413B1 (de) 2004-03-17
WO2000034284A1 (fr) 2000-06-15
JP2002531568A (ja) 2002-09-24
AR021533A1 (es) 2002-07-24

Similar Documents

Publication Publication Date Title
ATE261972T1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
ATE249460T1 (de) 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde
DE69606028D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung
ATE284392T1 (de) Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
ATE184708T1 (de) Polysiloxan-polyol makromere, deren herstellung und verwendung
DE69907698D1 (de) Azetidinderivate, deren herstellung und sie enthaltende arzneimittel
DE59814449D1 (de) Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
ATE310003T1 (de) Benzodiazepin-derivate, deren herstellung und anwendung
DE60034683D1 (de) 3(5)-ureido-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE69903464D1 (de) Haftverschlüsse, deren herstellung und sie aufweisenden produkten
ATE302604T1 (de) Thienylazolylalkoxyethanamine, deren herstellung und deren verwendung als medikamente
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
ATE308557T1 (de) Antipicornavirale verbindungen, deren herstellung und verwendung
DE60008419D1 (de) Farbstoffpräparate, deren herstellung und deren verwendung
ATE261959T1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
ATE242197T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE69204909D1 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
DE59802922D1 (de) 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung
DE59711704D1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
EP0672052A1 (de) Tachyquinin antagonisten, ihre herstellung und ihre verwendung in pharmazeutischen formulierungen.
DE59807020D1 (de) 1:2-chromkomplexfarbstoffe, deren herstellung und verwendung
DE69904199D1 (de) 1:2-chromkomplexfarbstoffe, deren herstellung und verwendung
DE59501950D1 (de) Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties